Fund moves
94 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 1, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 27, 2026 · Filed Mar 2, 2026
The CEO of Gilead Sciences sold $501K of Gilead Sciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$501,386
Shares × reported transaction price
17 days after results of Feb 10, 2026, 69 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $148.95 on Feb 27, 2026, within 5% of its 52-week high, after a 20% rise over the previous 30 trading days
52-week range $96.91 (May 9, 2025) to $155.80 (Feb 11, 2026), 88% of the way up, from 251 adjusted closes. 30 trading days earlier: $124.07 on Jan 14, 2026. Describes the past only, not a forecast
A WARN layoff notice covering 51 workers was filed in California on March 25, 2026.
From the official state WARN list, 26 days after the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.5% | −0.5% | +0.9% |
| 30 days | −5.5% | −3.6% | −1.9% |
| 90 days | −11.3% | +11.5% | −22.8% |
| 180 days | −1.0% | +12.8% | −13.8% |
Past results only. Not a forecast.
Fund moves
94 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 1, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Daniel Patrick O'day (Chairman & CEO) sold ~$1.37M of Gilead Sciences
Planned saleJohanna Mercier (Chief Comm & Corp Aff Officer) sold ~$433K of Gilead Sciences
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.